Retatrutide vs Tirzepatide vs Semaglutide: 2026 Research Comparison

The single-line answer

Semaglutide is a mono-agonist (GLP-1). Tirzepatide is a dual agonist (GLP-1 + GIP). Retatrutide is a triple agonist (GLP-1 + GIP + glucagon). Each added receptor extends the mechanism — and in published trials, the body-weight reduction has tracked that ranking.

Head-to-head trial data

The cleanest comparison comes from the headline body-weight reduction figures in each compound's pivotal trial. Numbers below are mean percentage reduction from baseline at the maximum approved or studied dose in each program.

What the glucagon arm actually adds

GLP-1 and GIP both work primarily on the intake side of energy balance — they slow gastric emptying, increase satiety, and improve insulin response to glucose. They are receptors expressed largely in the gut, pancreas, and central appetite circuits.

Glucagon is different. The glucagon receptor sits on the output side: it stimulates hepatic glycogenolysis, lipolysis in adipose tissue, and resting energy expenditure. In Lilly's design rationale for Retatrutide, the glucagon component is what unlocks an effect on energy burn rather than only intake. It's also what makes the dosing harder to balance — too much glucagon raises plasma glucose, which is why the molecule is engineered with specific receptor potency ratios.

Mechanism summary

• Semaglutide — GLP-1 only. Strong appetite suppression, insulinotropic effect, slowed gastric emptying.
• Tirzepatide — adds GIP. Synergistic effect on insulin sensitivity, potentially better glucose handling and weight reduction than GLP-1 alone.
• Retatrutide — adds glucagon receptor activation on top of GLP-1 + GIP. Adds an energy-expenditure / lipolytic mechanism the other two don't have.

Practical research differences

Dosing ranges studied

In the published Phase 2 trial, Retatrutide was studied at 1 mg, 4 mg, 8 mg, and 12 mg weekly doses, with dose escalation over the first 12-16 weeks. Tirzepatide ranges from 5 mg to 15 mg weekly; Semaglutide from 0.25 mg to 2.4 mg weekly. The molar potency and the receptor balance shift across these compounds, so dose numbers are not directly comparable in the way they are within a single drug class.

Half-life and reconstitution

All three are once-weekly molecules with similar lyophilized-powder reconstitution practices for research use: bacteriostatic water, gentle swirling (not vortexing), refrigerated storage of the reconstituted vial. Retatrutide's larger peptide mass (≈ 4731 Da) is consistent with its triple-receptor design.

Stability of supply in 2026

Tirzepatide and Semaglutide reference material has been widely available to research labs for several years; Retatrutide reference material is a newer addition to the catalog and supply is tighter. This is one of the reasons we list Retatrutide as a flagship product — securing HPLC-verified material with batch-level COA at consistent purity (≥ 99%) is harder for a Phase-3-stage compound than for already-approved ones.

Why Retatrutide leads the REVIVE catalog

Across our UAE research customer base, Retatrutide has been the highest-demand peptide of 2026. Three things drive that:

1. Phase 2 trial numbers. A 24% body-weight reduction at 48 weeks puts Retatrutide ahead of every prior incretin compound in head-to-head conditions.
2. Mechanism novelty. The glucagon arm is the first genuinely new pharmacology in the incretin class since GIP was added in Tirzepatide.
3. Research timing. The compound is in Phase 3 but not yet approved, which is the window where reference-material demand from independent research labs is highest.

Where the other two still fit

Retatrutide is not strictly "better" — it is broader. For a researcher whose protocol is focused on GLP-1-specific signaling, Semaglutide is the cleaner tool. For studies on the GLP-1 + GIP interaction without confounding glucagon effects, Tirzepatide is the right reference compound. Choosing among the three is a mechanism question first, not a magnitude question.

Companion peptides commonly stacked in research protocols

In our customer protocols, Retatrutide and Tirzepatide research is most often paired with two other compounds:

• Tesamorelin — a GHRH analogue used in lipodystrophy / visceral-adipose research. Mechanistically separate from incretins, often run in parallel.
• GHK-Cu — copper tripeptide used in skin and connective-tissue research. Frequently stacked for studies on the dermatological side-effects of rapid weight reduction.

Frequently asked questions

Is Retatrutide stronger than Tirzepatide?

On the single endpoint of body-weight reduction in published trials, the Phase 2 Retatrutide data shows a higher mean reduction (≈ 24.2%) than the Phase 3 Tirzepatide data (≈ 22.5%). However, trial duration and stage differ, and "stronger" depends on which endpoint is measured. Glycemic control comparisons are still emerging.

When will Retatrutide be FDA approved?

Lilly's Phase 3 TRIUMPH program is ongoing through 2026. An FDA approval decision is not expected before 2027 at the earliest, and approval is never guaranteed at this stage. Until then, Retatrutide remains a research-only compound.

Can the three peptides be compared on side effect profile?

Within the GLP-1 class, gastrointestinal effects (nausea, transient appetite loss) are dose-dependent and reduced by titration. The glucagon component in Retatrutide adds the possibility of small elevations in heart rate and modest changes in glycemic parameters that the dual and mono agonists don't produce. Direct head-to-head safety data will require Phase 3 readout.